Category: Latest News
-
J&J makes takeover approach for Swiss drugmaker Actelion: Bloomberg
(Reuters) – U.S. healthcare company Johnson & Johnson has approached Swiss biotechnology firm Actelion Ltd about a potential takeover, Bloomberg reported on Thursday, citing people it said were familiar with the matter. The report said deliberations were still at an early stage following Johnson & Johnson's (J&J) initial offer, and Actelion was working with an…
-
Lilly’s drug for Alzheimer’s fails big trial; shares drop
The failure of Eli Lilly and Co’s Alzheimer’s treatment to slow declines in mental capacity of patients with even mild symptoms cast serious doubt over whether a long-held approach to the memory-robbing disease could provide meaningful benefit to millions of people at risk. Many investors and families had been counting on solanezumab to become the…
-
U.S. Senate panel postpones Mylan hearing
The U.S. Senate Judiciary Committee on Monday postponed a hearing planned for next week to discuss Mylan NV's pending $465 million settlement to resolve charges that it underpaid government healthcare programs by misclassifying its EpiPen emergency allergy treatment. Mylan, the Justice Department and the Centers for Medicare and Medicaid Services had all declined to send…
-
Roche confident in Alzheimer’s program, despite Lilly flop
Roche said on Wednesday it still believed drugs targeting a protein called beta amyloid had potential to help fight Alzheimer’s disease, despite the high-profile failure of such a product from Eli Lilly. As the setback sent shares in Lilly skidding, Roche pointed out there were significant differences between two experimental Alzheimer’s drugs it was developing…
-
Roche confident in Alzheimer’s program, despite Lilly flop
Roche said on Wednesday it still believed drugs targeting a protein called beta amyloid had potential to help fight Alzheimer’s disease, despite the high-profile failure of such a product from Eli Lilly. As the setback sent shares in Lilly skidding, Roche pointed out there were significant differences between two experimental Alzheimer’s drugs it was developing…
-
Alzheimer’s setback prompts rethink of Lilly, Biogen stock outlooks
By Lewis Krauskopf NEW YORK (Reuters) – Eli Lilly & Co’s massive setback for its experimental Alzheimer’s disease treatment on Wednesday sent investors scrambling to re-evaluate shares of the U.S. drugmaker and those of companies making competing therapies, including biotech stalwart Biogen Inc. Lilly shares tumbled 10.5 percent, and fell to their lowest point in…